GL1X · GenesisL1 explorer

MolNFT v1 · #134674 · protein

Structure-based optimization of 1H-imidazole-2-carboxamides as axl kinase inhibitors utilizing a mer mutant surrogate

5TC0 · Tyrosine-protein kinase mer: “Structure-based optimization of 1H-imidazole-2-carboxamides as axl kinase inhibitors utilizing a mer mutant…”. X-ray diffraction, 1 ligand (79Y), 5 pockets (best druggability 0.66). MolNFT v1 #134674 on…

PDB
5TC0
Type
protein
Length
488 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tyrosine-protein kinase mer
EC
2.7.10.1
UniProt
Q12866
Ligands
79Y
Pockets
5 · best druggability 0.66

Structure

x-ray diffraction · 2 distinct chains · 40% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein kinase mer (EC 2.7.10.1)protein23837% helix, 21% strandQ12866
BTyrosine-protein kinase mer (EC 2.7.10.1)protein25043% helix, 16% strandQ12866

Ligands and binding sites

  • 79Y · N-(2-{4-[(2S)-4-(methylsulfonyl)morpholin-2-yl]-1,3-thiazol-2-yl}phenyl)-1H-imidazole-2-carboxamide · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13250.660.8135empty
23900.640.783579Y
32260.490.7537empty
41500.470.7718empty
51100.460.7820empty

Interfaces

1 interface between chains.

  • A–B · 965 Ų buried · 13 hydrogen bonds · protein-protein

Compared structures

  • 5TC0 · Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q12866 · AlphaFold monomer V2.0 prediction for tyrosine-protein kinase mer (Q12866) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.